Osteosarcoma - Pipeline Review, H1 2018

  • ID: 4464932
  • Report
  • 421 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AntiCancer Inc
  • APEIRON Biologics AG
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • MORE
Osteosarcoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2018, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 21, 7, 19 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AntiCancer Inc
  • APEIRON Biologics AG
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • MORE
Introduction

Osteosarcoma - Overview

Osteosarcoma - Therapeutics Development

Osteosarcoma - Therapeutics Assessment

Osteosarcoma - Companies Involved in Therapeutics Development

Osteosarcoma - Drug Profiles

Osteosarcoma - Dormant Projects

Osteosarcoma - Discontinued Products

Osteosarcoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Osteosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2018

Osteosarcoma - Pipeline by Amgen Inc, H1 2018

Osteosarcoma - Pipeline by AntiCancer Inc, H1 2018

Osteosarcoma - Pipeline by APEIRON Biologics AG, H1 2018

Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018

Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Osteosarcoma - Pipeline by Bayer AG, H1 2018

Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Osteosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Osteosarcoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H1 2018

Osteosarcoma - Pipeline by Cellestia Biotech AG, H1 2018

Osteosarcoma - Pipeline by Cellmid Ltd, H1 2018

Osteosarcoma - Pipeline by CorMedix Inc, H1 2018

Osteosarcoma - Pipeline by Eisai Co Ltd, H1 2018

Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H1 2018

Osteosarcoma - Pipeline by Endocyte Inc, H1 2018

Osteosarcoma - Pipeline by Exelixis Inc, H1 2018

Osteosarcoma - Pipeline by Intezyne Technologies Inc, H1 2018

Osteosarcoma - Pipeline by Ipsen SA, H1 2018

Osteosarcoma - Pipeline by Isofol Medical AB, H1 2018

Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Osteosarcoma - Pipeline by MacroGenics Inc, H1 2018

Osteosarcoma - Pipeline by Mateon Therapeutics Inc, H1 2018

Osteosarcoma - Pipeline by MD Biosciences GmbH, H1 2018

Osteosarcoma - Pipeline by Merck & Co Inc, H1 2018

Osteosarcoma - Pipeline by Merck KGaA, H1 2018

Osteosarcoma - Pipeline by Nektar Therapeutics, H1 2018

Osteosarcoma - Pipeline by Novartis AG, H1 2018

Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H1 2018

Osteosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Osteosarcoma - Pipeline by Pfizer Inc, H1 2018

Osteosarcoma - Pipeline by Scancell Holdings Plc, H1 2018

Osteosarcoma - Pipeline by Sorrento Therapeutics Inc, H1 2018

Osteosarcoma - Pipeline by Teijin Pharma Ltd, H1 2018

Osteosarcoma - Pipeline by Tyme Technologies Inc, H1 2018

Osteosarcoma - Dormant Projects, H1 2018

Osteosarcoma - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Osteosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advenchen Laboratories LLC
  • Amgen Inc
  • AntiCancer Inc
  • APEIRON Biologics AG
  • Arrowhead Pharmaceuticals Inc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celldex
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll